Figure 5

Figure 5

CysLT₁ antagonists reduce cell viability in uveal melanoma cell lines. Graphs represent the effects of treatment with varying concentrations of dacarbazine (DTIC), quininib (Q1), 1,4-dihydroxy quininib (Q7), montelukast (Mon), and HAMI 3379 (HAMI) for 24 and 96 h in Mel285 (A,E) (n = 3/n = 6), OMM2.5 (B,F), (n = 3/n = 4), Mel270 (C,G) (n = 3) and ARPE-19 (D,H) (n = 4/n = 6) cell lines. Treatment with 50 μM of quininib, 1,4-dihydroxy quininib, and montelukast for 96 h significantly reduced cell viability in Mel285 (E), OMM2.5 (F), and Mel270 (G) cells. (D) Quininib analogues had no effect on ARPE-19 cells at 10 or 50 μM following 24 treatment. (H) 50 μM of quininib reduced ARPE-19 viability at 96 h. Viability of cells was determined using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. 5000 cells were seeded and treated in triplicate for each individual experiment. Statistical analysis was performed by ANOVA with Dunnett’s post hoc multiple comparison test. Error bars are mean + S.E. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.